本报告依据中国资产评估准则编制 成都先导药物开发股份有限公司拟增资所涉及的 成都先衍生物技术有限公司 股东全部权益价值 资产评估报告 中天华资评报字[2026]第10249号 (共1册, 第1册) 北京中 间责任公司 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020122202600199 | | | --- | --- | --- | | 合同编号: | 中天华合同字[2026]第P0251号 | | | 报告类型: | 法定评估业务资产评估报告 | | | 报告文号: | 中天华资评报字[2026]第10249号 | | | 报告名称: | 成都先导药物开发股份有限公司拟增资所涉及的成都先衍生物技 术有限公司股东全部权益价值资产评估报告 | | | 评估结论: | 453,960,000.00元 | | | 评估报告日: | 2026年02月26日 | | | 评估机构名称: | 北京中天华资产评估有限责任公司 | | | 签名人员: | 彭跃龙 (资产评估师) 正式会员 编号: 1120068 | | | | 郝伟涛 见习会员 编号:11240048 | (资产评估师) | ...

二〇二六年三月 1 成都先导药物开发股份有限公司 2026 年第一次临时股东会会议资料 证券代码：688222 证券简称：成都先导 成都先导药物开发股份有限公司 2026 年第一次临时股东会会议资料 为维护全体股东的合法利益，确保股东会的正常秩序和议事效率，保证大会 的顺利进行，成都先导药物开发股份有限公司（以下简称"公司"或"成都先导"）根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《成都先导药物开发股份有限公司章程》（以下 简称"《公司章程》"）及《成都先导药物开发股份有限公司股东会议事规则》（以 下简称"《股东会议事规则》"）及相关规定，特制定本须知。 一、为确认出席大会的股东或代理人或其他出席者的出席资格，会议工作人 员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签 到手续，并请按规定出示身份证明文件或法定代表人/执行事务合伙人委派代表身 份证明书、授权委托书等相关文件，经验证后方可出席会议，公司有权拒绝不符 合条件的人士进入会场。会议开始后，由会议 ...

成都先导公告称，公司拟召开2026年第一次临时股东会，审议关于增资参股公司暨关联交易的议案。先 衍生物为公司参股公司暨关联方，拟融资不超1.5亿元。交易前公司持有其23.20%股权，此次拟按4.5亿 元投前估值，以2400万元认购新增注册资本，交易后持股比例待定。领投方为道远国生，公司关联方曹 家铭、华博器械分别增资350万元、300万元，构成关联交易，但不构成重大资产重组。该议案已获董事 会审议通过。 ...

Core Insights - The CRO (Contract Research Organization) industry in China is a strategic emerging industry that supports pharmaceutical innovation and is crucial for the transition from a pharmaceutical power to a pharmaceutical stronghold [1][9] - The development of policies for the CRO industry has evolved from a focus on the overall biopharmaceutical sector to specialized areas, emphasizing innovation, safety, and supply chain security [1][3] Policy Development History - The policy evolution from the "Tenth Five-Year Plan" to the "Fourteenth Five-Year Plan" has progressively recognized the importance of the CRO industry, with increasing support for specialized services [1] - The "Fifteenth Five-Year Plan" emphasizes differentiated, high-value innovation alongside supply chain security [1] National Policy Summary and Interpretation - Since 2006, multiple national policies have been introduced to support the CRO service system, focusing on regulatory standards, clinical trial optimization, and international development [3][7] - Key policies include the establishment of the MAH (Marketing Authorization Holder) system and the optimization of review and approval processes [3][7] Key National Policies (2025 Outlook) - Policies from 2006 to 2025 highlight the strategic importance of biopharmaceuticals and the CRO industry, with a focus on enhancing innovation capabilities and regulatory frameworks [4][5][6] - Recent policies aim to streamline clinical trial approvals and support the development of innovative drugs [6][10] Provincial and Municipal Policy Summary - Various provinces and cities have implemented supportive policies for the CRO industry, including investment subsidies, revenue rewards, and insurance subsidies, with some regions offering up to 50 million yuan in support [11][12] - Specific measures include allowing foreign investment in CROs and promoting AI integration in the industry [11][12][14] Provincial Development Goals - Regions like the Yangtze River Delta focus on high-end CRO service systems, while the Beijing-Tianjin-Hebei area emphasizes collaborative innovation and full-chain outsourcing [14] - Local governments aim to enhance the scale and service capabilities of the biopharmaceutical industry, with targeted initiatives for specific sectors such as seed industry CROs in Hainan [14]

股票近期走势 经济观察网成都先导公告拟以2400万元增资参股公司先衍生物，投前估值为4.5亿元。先衍生物专注于 小核酸新药研发，其针对高血压的药物LDR2402已进入Ⅱ期临床，治疗肥胖的药物LDR2515近期获临床 试验默示许可。此次增资由道远国生领投，融资总额不超过1.5亿元，交易后成都先导持股比例将根据 融资结果调整。 以上内容基于公开资料整理，不构成投资建议。 近7日，成都先导股价区间波动，收盘价从29.84元至30.26元，区间振幅达13.48%。资金流向显示主力 资金分化，如2月10日主力净流入4528万元，但2月11日净流出1256万元。截至2月12日，换手率 2.04%，单日涨幅1.44%。 ...

Core Viewpoint - The report from Guolian Minsheng Securities highlights the synergistic effects of small nucleic acid drugs and GLP-1 class drugs in the weight loss sector, suggesting they could become a "golden duo" for weight management [1][4]. Group 1: Drug Efficacy and Development - Arrowhead has reported promising initial weight loss results from two small nucleic acid drugs targeting INHBE and ALK7, with ARO-INHBE showing an average fat reduction of 9.9% and liver fat reduction of up to 38.6%, alongside a 3.6% increase in lean tissue [1]. - ARO-ALK7 demonstrated a dose-dependent average reduction of ALK7 mRNA by 88%, confirming the TRiM platform's ability to inhibit fat cell gene expression [1]. - Wave Life's WVE-007 targeting liver INHBE showed a 9.4% reduction in visceral fat and a 4.5% overall fat reduction after three months, with a 3.2% increase in lean body mass [3]. Group 2: Market Trends and Collaborations - Major pharmaceutical companies are increasingly investing in small nucleic acid drugs, with Eli Lilly committing $1.2 billion in collaboration with Saint Inbiotech for RNAi candidate drug development for metabolic diseases [3]. - Eli Lilly also invested $1 billion in HAYA's lncRNA platform for obesity and related metabolic disease treatments, while Novo Nordisk partnered with Replicate Bioscience for a $550 million project targeting obesity and type 2 diabetes [3]. - The speed of Chinese pharmaceutical companies in developing small nucleic acid drugs for weight loss is nearly on par with international counterparts, with several companies like Hengrui Medicine and Innovent Biologics actively pursuing this area [5]. Group 3: Investment Recommendations - The report suggests focusing on companies involved in small nucleic acid weight loss targets, including Hengrui Medicine, Chengdu Xian Dao, China National Pharmaceutical Group, East China Pharmaceutical, and others [6].

Group 1 - The company, Chengdu XianDao Pharmaceutical Development Co., Ltd., will hold its first extraordinary general meeting of shareholders in 2026 on March 2, 2026, at 14:00 [1][4] - The meeting will be conducted using a combination of on-site and online voting methods [1][3] - The on-site meeting will take place at the company's office located in Chengdu, Sichuan Province [1][4] Group 2 - The online voting system will be provided by the Shanghai Stock Exchange, with voting available from 9:15 to 15:00 on the day of the meeting [2][3] - Shareholders must register to attend the meeting by submitting required documents by February 27, 2026 [12][14] - The company will disclose meeting materials on the Shanghai Stock Exchange website prior to the meeting [4] Group 3 - There are no special resolutions or proposals for minority shareholders to vote separately [5] - Certain related shareholders are required to abstain from voting on specific proposals [5] - The meeting will be attended by registered shareholders, company directors, senior management, and appointed lawyers [8][9]

证券代码：688222 证券简称：成都先导 公告编号：2026-006 成都先导药物开发股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第一次临时股东会 召开日期时间：2026 年 3 月 2 日 14 点 00 分 召开地点：成都市双流区慧谷东一路 8 号天府国际生物城 C2 栋成都先导药 物开发股份有限公司二楼大会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 3 月 2 日 至2026 年 3 月 2 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东会召开日期：2026年3月2日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日 ...

Group 1 - The core point of the article is that Chengdu XianDao (688222) plans to invest 24 million yuan in Chengdu XianYan Biological Technology Co., Ltd. at a pre-investment valuation of 450 million yuan [2] - Chengdu XianYan is a subsidiary and related party of Chengdu XianDao, with a registered capital of 17.2408 million yuan, and aims to raise no more than 150 million yuan for its development [2] - The company has established an innovative technology system including novel small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology, focusing on chronic disease treatment [2] Group 2 - The investment will increase Chengdu XianDao's stake in Chengdu XianYan, which currently holds 23.2% of the equity, with the final ownership percentage to be determined based on the total financing amount and the new registered capital [2]

证券代码：688222 证券简称：成都先导 公告编号：2026-005 成都先导药物开发股份有限公司 关于增资参股公司暨关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 至本公告披露日，成都先导药物开发股份有限公司（以下简称"成都 先导"或"公司"）过去 12 个月与同一关联人先衍生物进行的日常关联交易金 额为 1,287.44 万元，未超过董事会审议的日常关联交易金额；与本次交易累 计已达到股东会审议标准，尚需提交公司股东会审议。 公司过去 12 个月与关联方曹家铭、拉萨经济技术开发区华博医疗器械有 限公司（以下简称"华博器械"）均未发生关联交易。 交易实施尚需履行的审批及其他相关程序 本次关联交易已经公司第三届董事会第五次会议审议通过，关联董事已回避 表决。独立董事专门会议对本次交易事项进行了事先审议，全体独立董事一致同 意该交易事项。本次关联交易事项达到股东会审议标准，尚需提交股东会审议。 其它需要提醒投资者重点关注的风险事项 本次对参股企业先衍生物增资，各方均在履行内部签约流程，尚未完成实际 ...